The firm expects to launch a 510(k)-cleared version of its Bladder EpiCheck recurrence assay early next year followed by an RUO early-stage lung cancer assay.
Children's Hospital Los Angeles used a SARS-CoV-2 sequencing panel to determine if patients had become infected from the same source as healthcare workers.
The UK Department of Health and Social Care has already ordered 10,000 RNA test cartridges from the company, which expects to obtain a CE-IVD mark for its test within weeks.
Fluidigm's Biomark HD microfluidic platform will enable more than 180,000 real-time PCR tests to be run over the next 90 days to potentially support COVID-19 screening.
Combining Ubiquitome's handheld PCR device and Oxford Nanopore's sequencer may enable a single person to screen 500 samples and obtain 24 whole genome sequences per day.
The researchers said their assay can be run in 30 to 45 minutes, with 95 percent positive predictive agreement and 100 percent negative predictive agreement.
Direct-to-consumer genetic testing companies are searching for a genetic reason for why some people, but not others, become gravely ill with COVID-19, the Detroit Free Press reports.
In PNAS this week: forward genetics-base analysis of retinal development, interactions of T cell receptors with neoantigens in colorectal cancer, and more.
